Product Overview
Compound: PT‑141 (Bremelanotide)
Format: Lyophilized Powder
Purity: ≥ 98%
Contents: 10 mg per vial, sterile sealed
Storage: Store lyophilized powder in a cool, dry place. Refrigerate after reconstitution.
For laboratory research use only. Not for human consumption.
Batch-specific third-party analysis confirms identity, purity, and sterility. Request COA by emailing providers@theratideusa.com.
PT‑141 (Bremelanotide) is a cyclic peptide analog of α-MSH, acting as a melanocortin receptor agonist (MC3R/MC4R). It was originally developed for erectile dysfunction and later approved in 2019 (brand name Vyleesi) for hypoactive sexual desire disorder in premenopausal women :contentReference[oaicite:1]{index=1}.
- Erectile Function: Dose-dependent erections observed in rats, primates, and human males :contentReference[oaicite:2]{index=2}.
- Hypoactive Sexual Desire Disorder (HSDD): Improved sexual desire and reduced distress in Phase III women trials :contentReference[oaicite:3]{index=3}.
- Onset & Side Effects: Effects begin ~30–45 minutes post-dose; common side effects include flushing, nausea, and increases in blood pressure :contentReference[oaicite:4]{index=4}.
These findings are based on controlled clinical studies.
This product is sold for research purposes only and is not a dietary supplement or intended for human use. Review our Terms & Conditions before purchasing.
Safety Notice: Keep out of reach of children. For use only by trained professionals in a laboratory setting. Improper use could cause adverse effects.
FDA Notice: Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease.
